Skip to main content

Table 1 Characteristics of HCV treatment commenced patients in community settings

From: Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings

VariablesN (%)
Sex (n = 315)Male212 (67.3)
Female103 (32.7)
HCV genotype (n = 315)1156 (49.7)a
29 (2.9)
3148 (47.1)
41 (0.3)
62 (0.6)
Age≤3027 (8.6)
31–4087 (27.6)
41–50112 (35.6)
51–6070 (22.2)
> 6019 (6.0)
Currently or recently drugs useb (n = 225)Yes95 (44.2)
No130 (57.8)
Receiving OST (n = 314)Yes87 (27.7)
No227 (72.3)
Antipsychotics use (n = 315)Yes111 (35.2)
No204 (64.8)
Prior HCV treatmentPeg-IFN or IFN plus Rib7 (2.2)
DAA6 (1.9)
No302 (95.9)
Cirrhotic patientsYes29 (9.2)
No286 (90.8)
FibroScan ≥ 12.5 kPa (n = 112)Yes4 (3.6)
No108 (96.4)
APRI ≥ 1 (n = 308)Yes46 (14.9)
No262 (85.1)
Prescribed DAA (n = 314)Sofosbuvir plus Daclatasvir112 (35.7)
Sofosbuvir plus Ledipasvir95 (30.2)
Epclusa62 (19.7)
Zepatier31 (9.9)
Sofosbuvir plus Velpatasvir10 (3.2)
Paritaprevir/ritonavir plus Ombitasvir plus Dasabuvir3 (1)
Elbasvir/Grazoprevir1 (0.3)
Treatment duration (n = 315)8 weeks3 (1)
12 weeks300 (95.2)
24 weeks12 (3.8)
  1. aone patient with genotype 1 and 3, one patient with genotype 1 and 6, and one patient with undetected genotype
  2. b: Currently using drug or used drug within 6 months before the treatment
  3. OST opioid substitute treatment, APRI Aspartate Aminotransferase to Platelet Ratio Index
  4. Peg-IFN: Pegylated interferon
  5. IFN interferon
  6. Rib ribavirin